Microbiology of Diabetic Foot Infections
DOI:
https://doi.org/10.51481/amc.v63i4.1211Keywords:
Osteomyelitis, Diabetic Foot, MicrobiologyAbstract
Aim: Describe and characterize the microbiology of diabetic foot osteomyelitis (DFO) in hospitalized patients of the San Juan de Dios Hospital in 2018.
Methods: The local database of patients of the Diabetic Foot Unit was consulted to obtain the demographic data of hospitalized patients with a diagnosis of osteomyelitis in addition to the information system of the Microbiology division of the Clinical Laboratory to obtain data on species bacteria and their antimicrobial susceptibility profiles isolated from the respective bone samples. With these data, a database for the project was built and the descriptive statistical analysis was carried out in Excel spreadsheets.
Results: Enterococcus faecalis was the most frequently isolated agent (21%), followed by Staphylococcus aureus (14%) of which 70% presented a methicillin resistance phenotype, and Escherichia coli as third place (11%). Other Gram negative bacilli occupied a fourth place, being Enterobacter cloacae (8%) and Klebsiella pneumoniae (8%) the main isolated species; it should be noted the presence of 24% of strains carrying extended spectrum β-lactamases, with K. pneumoniae as the main carrier species of this resistance phenotype.
Conclusion: E. faecalis was reported for the first time as the most isolated bacterium in DFO, which allows to conclude that the microbiology of these conditions in Costa Rica differ from that reported in the international literature and it is necessary to update the Costa Rican medical community. It is also important to note that even though the percentage obtained from Gram negative rods carrying ESBL is lower than that reported in the literature, 100% of the K. pneumoniae strains were carriers of this resistance phenotype, therefore it is possible consider at the local level that the preliminary finding of this species should modify the therapeutic spectrum to be used pending final reports.
Downloads
References
Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA. 2005; 293: 217-228.
Kimberlee B. Hobizal, DPM and Dane K. Wukich, MD. Diabetic foot infections: current concept review. Diabetic Foot & Ankle. 2012; 3: 18409
Abdulrazak A, Bitar ZI, Al-Shamali AA. Bacteriological study of diabetic foot infections. J Diabetes Complications.2005; 19:138-141
Miller A, Henry M. Update in diagnosis and treatment of diabetic foot infections. Phys Med Rehabil Clin N Am. 2009; 20: 611-625
Newman LG, Waller J, Palestro CJ, et al. Unsuspected osteomyelitis in diabetic foot ulcers. Diagnosis and monitoring by leukocyte scanning with indium in 111 oxyquinoline. JAMA 1991; 266: 1246-1251.
Zimmerli W, Fluckiger U. Classification and microbiology of osteomyelitis. Orthopade. 2004; 33(3): 267-272.
Lipsky BA, Berendt AR, Deery HG, Embil JM, Joseph WS, Karchmer AW, et al. Infectious Diseases Society of America. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2004; 39: 885-910.
Game F, Jeffcoate W. MRSA and osteomyelitis of the foot in diabetes. Diabet Med. 2004; 21(Suppl 4):16-9.
Hatipoglu M, Mutluoglu M, Turhan V, Uzun G, Lipsky A, Sevim E, et al. Causative pathogens and antibiotic resistance in diabetic foot infections: a prospective multi-center study. Journal of Diabetes and its Complications. 2016; 30: 910-916
Hartemann-Heurtier A, Senneville E. Diabetic foot osteomyelitis. Diabetes & metabolism. 2008; 34: 87-95.
Citron DM, Goldstein EJ, Merriam CV. Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. J Clin Microbiol. 2007; 45:2819-2828.
Saltoglu N, Ergonul O, Tulek N, Yemisen M, Kadanali A, Karagoz G, et al. Influence of multidrug resistant organisms on the outcome of diabetic foot infection. International Journal of Infectious Diseases. 2018; 70:10-14.
Nakai H, Hagihara M, Kato H, Hirai J, Nishiyama N, Koizumi Y, Sakanashi D, Suematsu H, Yamagishi Y, Mikamo H. Prevalence and risk factors of infections caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae. Journal of Infection and Chemothery. 2016; 22(5):319-26.
Rattanaumpawan P, Choorat C, Takonkitsakul K, Tangkoskul T, Seenama C, Thamlikitkul V. A prospective surveillance study for multidrug-resistant bacteria colonization in hospitalized patients at a Thai University Hospital. Antimicrobial Resistance Infection Control. 2018; 7:102.
Doernberg SB, Winston LG. Risk factors for acquisition of extended-spectrum β-lactamase-producing Escherichia coli in an urban county hospital. American Journal of Infection Control. 2012; 40(2):123-7
Briongos-Figuero LS, Gómez-Traveso T, Bachiller-Luque P, Domínguez-Gil González M, Gómez-Nieto A, Palacios-Martín T, González-Sagrado M, Dueñas-Laita A, Pérez-Castrillón JL. Epidemiology, risk factors and comorbidity for urinary tract infections caused by extended-spectrum beta-lactamase (ESBL)-producing enterobacteria. International Journal of Clinical Practice. 2012; 66(9):891-6.
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Los autores que publican en la revista Acta Médica Costarricense pueden distribuir, copiar, remezclar, retocar, leer, descargar, imprimir, buscar y crear a partir de su obra de modo no comercial, indicando los créditos a la revista y sus autores y compartir su obra en las mismas condiciones. Para ello se aplica la licencia Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional(CC BY-NC-SA 4.0)
